<DOC>
	<DOC>NCT01622556</DOC>
	<brief_summary>This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity conditioning and 2 unit UCB stem cell transplant in a single institution setting in patients with hematologic malignancies for whom allogeneic transplantation is indicated.</brief_summary>
	<brief_title>Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Subjects 1870 years old. ECOG 02 Patients must have a diagnosis of one of the following: Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Hodgkin's Disease NonHodgkins Lymphoma Myelodysplastic Syndromes Myeloproliferative Disorder Patients must have adequate visceral organ function Patients must furnish written informed consent and HIPAA authorization for release of personal health information. Patients must be able to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments. Patients who have a histocompatible siblingmatched donor age 18 to 65 years in good health who is willing to donate stem cells are ineligible. Patients who are pregnant are ineligible. Patients are ineligible if they have received cumulative chemotherapy doses in excess of: carmustine (BCNU) 400 mg/m2, and/or a cumulative anthracycline exposure in excess of 550 mg/m2 doxorubicin (AdriamycinÂ®) unless gatedpool radionuclide cardiac scan shows greater than/equal to 45% ejection fraction. Patients who are HIV or HTLVI, II antibody seropositive are ineligible.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Hodgkin's Disease</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Myeloproliferative Disorder</keyword>
</DOC>